Boundless Bio, INC. (BOLD) — SEC Filings

Overview

Boundless Bio, INC. (BOLD) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 13, 2026: On April 13, 2026, Boundless Bio, Inc. filed an 8-K report detailing the termination of a material definitive agreement and the creation of a direct financial obligation. The specific details of the agreement and the financial obligation are not provided in this summary.

Sentiment Summary

Across 22 filings, the sentiment breakdown is: 2 bearish, 20 neutral. The dominant filing sentiment for Boundless Bio, INC. is neutral.

Filing Type Overview

Boundless Bio, INC. (BOLD) has filed 8 8-K, 6 10-Q, 1 DEF 14A, 1 10-K, 1 SC 13D, 3 SC 13G, 1 S-1/A, 1 S-1 with the SEC between Mar 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (22)

• Boundless Bio Files 8-K: Agreement Termination & Financial Obligation — 8-K · Apr 13, 2026 Risk: medium
  On April 13, 2026, Boundless Bio, Inc. filed an 8-K report detailing the termination of a material definitive agreement and the creation of a direct financial o
• Boundless Bio Narrows Q3 Loss Amidst R&D Cuts, Cash Dwindles — 10-Q · Nov 5, 2025 Risk: high
  Boundless Bio, Inc. reported a net loss of $13.879 million for the three months ended September 30, 2025, an improvement from the $16.509 million net loss in th
• Boundless Bio's Q2 Net Loss Widens to $29.8M Amid R&D Surge — 10-Q · Aug 5, 2025 Risk: high
  Boundless Bio, Inc. (BOLD) reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage as a pharmaceutical pr
• Boundless Bio Files 8-K on Security Holder Votes — 8-K · Jun 23, 2025 Risk: low
  Boundless Bio, Inc. filed an 8-K on June 23, 2025, to report on matters submitted to a vote of its security holders. The filing does not contain specific detail
• Boundless Bio Files 8-K on Exit Costs and Other Events — 8-K · May 23, 2025 Risk: medium
  On May 23, 2025, Boundless Bio, Inc. filed an 8-K report detailing cost associated with exit or disposal activities and other events. The company, incorporated
• Boundless Bio Files Q1 2025 10-Q — 10-Q · May 9, 2025 Risk: medium
  Boundless Bio, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported its financial position and results of operations. Key financial da
• Boundless Bio Files 2025 Proxy Statement — DEF 14A · Apr 29, 2025 Risk: low
  Boundless Bio, Inc. filed its definitive proxy statement on April 29, 2025, for its annual meeting. The filing details the company's board of directors, executi
• Boundless Bio Files 8-K: Material Agreement & Exhibits — 8-K · Apr 1, 2025 Risk: medium
  On April 1, 2025, Boundless Bio, Inc. filed an 8-K report. The filing primarily concerns the entry into a material definitive agreement and the inclusion of fin
• 10-K Filing — 10-K · Mar 27, 2025
• Boundless Bio C-Suite Shakeup — 8-K · Dec 12, 2024 Risk: medium
  On December 6, 2024, Boundless Bio, Inc. announced the departure of Dr. Peter Blume-Jensen from his roles as Chief Medical Officer and Chief Scientific Officer.
• Boundless Bio Q3 2024 10-Q Filed — 10-Q · Nov 7, 2024 Risk: medium
  Boundless Bio, Inc. filed its 10-Q for the period ending September 30, 2024. The company's financial statements show various equity and debt instruments, includ
• Arch Venture Funds Disclose Stake in Boundless Bio — SC 13D · Oct 29, 2024 Risk: medium
  ARCH Venture Fund IX, L.P. and related entities filed a Schedule 13D on October 29, 2024, regarding their beneficial ownership of Boundless Bio, Inc. The filing
• Boundless Bio Appoints New CMO, Director; CMO Departs — 8-K · Oct 15, 2024 Risk: medium
  On October 11, 2024, Boundless Bio, Inc. announced changes to its executive team and board of directors. Dr. Peter Blume-Jensen has resigned as Chief Medical Of
• Boundless Bio Appoints New CMO, Elects Director — 8-K · Aug 20, 2024 Risk: medium
  Boundless Bio, Inc. announced on August 19, 2024, the appointment of Dr. David M. Halbert as Chief Medical Officer and the election of Ms. Sarah E. Kelly to its
• Boundless Bio Files 10-Q, Details Financials — 10-Q · Aug 12, 2024 Risk: medium
  Boundless Bio, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial status, including details on its convertible preferre
• Boundless Bio, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 13, 2024 Risk: medium
  Boundless Bio, Inc. (BOLD) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Boundless Bio, Inc. filed a 10-Q for the quarterly period ended March 3
• SC 13G Filing — SC 13G · Apr 12, 2024
• SC 13G Filing — SC 13G · Apr 10, 2024
• SC 13G Filing — SC 13G · Apr 9, 2024
• Boundless Bio Files 8-K: Bylaws, Financials Updated — 8-K · Apr 2, 2024 Risk: low
  On April 2, 2024, Boundless Bio, Inc. filed an 8-K report. The filing primarily concerns amendments to its articles of incorporation or bylaws, and other events
• Boundless Bio, Inc. Files Amendment to Registration Statement — S-1/A · Mar 21, 2024 Risk: low
  Boundless Bio, Inc. (BOLD) filed a Amended IPO Registration (S-1/A) with the SEC on March 21, 2024. Boundless Bio, Inc. filed an S-1/A (Amendment No. 1) with th
• Boundless Bio Files S-1 Registration Statement for Proposed Public Offering — S-1 · Mar 6, 2024 Risk: low
  Boundless Bio, Inc. (BOLD) filed a IPO Registration (S-1) with the SEC on March 6, 2024. Boundless Bio, Inc. has filed an S-1 registration statement with the SE

Risk Profile

Risk Assessment: Of BOLD's 18 recent filings, 2 were flagged as high-risk, 11 as medium-risk, and 5 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Boundless Bio, INC.'s most recent 10-Q filing (Nov 5, 2025):

• Revenue: $0
• Net Income: $ -13,879,000
• EPS: $ -0.62
• Debt-to-Equity: 0.53
• Cash Position: $ 14,980,000
• Operating Margin: N/A
• Total Assets: $ 168,721,000
• Total Debt: $ 58,552,000

Key Executives

• Christian Hassig
• Klaus Wagner
• Neil Abdollahian
• Zachary Hornby
• Jami Rubin
• Dr. Peter Blume-Jensen
• Clinton Bybee
• Keith Crandell
• Kristina Burow
• Robert Nelsen
• Steven Gillis
• Dr. Robert J. Cervera
• Dr. David J. Earp
• Dr. David M. Halbert
• Ms. Sarah E. Kelly

Industry Context

Boundless Bio operates in the highly competitive and capital-intensive biotechnology sector, focusing on developing novel therapeutics. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Success hinges on scientific innovation, effective clinical trial execution, and securing substantial funding to navigate these challenges.

Top Tags

10-Q (4) · financials (4) · Biotechnology (3) · corporate-governance (3) · biotech (3) · IPO (3) · Oncology (2) · Cash Burn (2) · Net Loss (2) · Clinical Trials (2)

Key Numbers

• Net Loss (Q3 2025): $13.879M — Improved from $16.509M in Q3 2024
• Net Loss (YTD Sep 2025): $45.312M — Improved from $48.915M in YTD Sep 2024
• Research and Development Expenses (Q3 2025): $10.673M — Decreased from $14.089M in Q3 2024
• Research and Development Expenses (YTD Sep 2025): $35.028M — Decreased from $41.953M in YTD Sep 2024
• Cash and Cash Equivalents (Sep 30, 2025): $14.980M — Significant decrease from $26.587M at Dec 31, 2024
• Short-term Investments (Sep 30, 2025): $102.590M — Decreased from $125.527M at Dec 31, 2024
• Accumulated Deficit (Sep 30, 2025): $246.784M — Increased from $201.472M at Dec 31, 2024
• Net Cash Used in Operating Activities (YTD Sep 2025): $36.554M — Indicates ongoing cash burn
• Shares Outstanding (Oct 31, 2025): 22,385,611 — Reflects current share count
• Total Current Assets (Sep 30, 2025): $120.156M — Decreased from $154.390M at Dec 31, 2024
• Revenue: $0 — No revenue reported for Q2 2025, consistent with pre-commercial stage.
• Net Loss (Q2 2025): -$29.8M — Increased 34.8% from -$22.1M in Q2 2024, indicating higher operational costs.
• Net Loss (YTD Q2 2025): -$58.1M — Increased 32.3% from -$43.9M in YTD Q2 2024, reflecting sustained investment.
• R&D Expenses (Q2 2025): $24.2M — Up from $17.8M in Q2 2024, showing increased clinical trial activity.
• G&A Expenses (Q2 2025): $6.2M — Increased from $4.7M in Q2 2024, indicating higher administrative overhead.

Frequently Asked Questions